<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816842</url>
  </required_header>
  <id_info>
    <org_study_id>EC3184</org_study_id>
    <secondary_id>Prot 84 24/01/06</secondary_id>
    <nct_id>NCT00816842</nct_id>
  </id_info>
  <brief_title>Plasma Citrulline Concentration in Tropical Enteropathy</brief_title>
  <official_title>Plasma Citrulline as Quantitative Biomarker of HIV Associate Villous Atrophy in a Tropical Enteropathy Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Parma</source>
  <brief_summary>
    <textblock>
      Citrulline is an amino acid produced in the intestine and in the liver, but the liver does&#xD;
      not contribute significantly to circulating citrulline concentrations. The intestine is thus&#xD;
      the only organ that normally releases significant amounts of citrulline into the blood&#xD;
      stream. The investigators have designed a study looking at the value of measuring plasma&#xD;
      citrulline concentration in patients with tropical enteropathy of mixed HIV status. The focus&#xD;
      will be on the ability of the intestine to sustain the individual concerned from a&#xD;
      nutritional standpoint. The investigators hypothesise that plasma citrulline concentration is&#xD;
      a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related&#xD;
      enteropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary studies reported that plasma citrulline concentrations may be a reliable&#xD;
      biochemical marker for intestinal dysfunction and absorptive enterocyte mass. The&#xD;
      relationship between citrulline concentration and intestinal function has been supported in&#xD;
      other studies including those examining rejection in small bowel allografts. Concentrations&#xD;
      of citrulline are dramatically reduced in cases of mucosal damage (e.g. moderate graft&#xD;
      rejection or viral enteritis)and strongly correlate (inversely) with severity on biopsy.&#xD;
      Plasma citrulline concentration is lower also in patients with villous atrophy&#xD;
      (24±13µmol/L)than in healthy subjects (40±10µmol/L)and patients with anorexia nervosa&#xD;
      (39±9µmol/L).Experimental studies have been carried out also in assessing the value of&#xD;
      citrulline as a marker for severity of small bowel epithelial damage from radiation and viral&#xD;
      infections. The plasma citrulline was shown to be a simple, non invasive and sensitive essay&#xD;
      to monitor and quantify radiation and/or chemotherapy induced small bowel damage in mice and&#xD;
      humans. Otherwise, the literature on citrulline as a potential marker of intestinal and&#xD;
      nutritional integrity is young and consistent data for specific conditions as for HIV&#xD;
      enteropathy are missing.We hypothesise that plasma citrulline concentration is a marker of&#xD;
      small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>postabsorptive plasma citrulline concentration</measure>
    <time_frame>within two years since enrolment date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intestinal permeability ratio</measure>
    <time_frame>within two years since enrolment date</time_frame>
  </secondary_outcome>
  <condition>Malabsorption Syndromes</condition>
  <condition>Granulomatous Enteritis</condition>
  <condition>Enteritis</condition>
  <condition>HIV Enteropathy</condition>
  <condition>Ileal Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Tropical enteropathy with mixed HIV status&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically ascertained Tropical enteropathy&#xD;
&#xD;
          -  Mixed HIV status&#xD;
&#xD;
          -  Body mass index within normal range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with surgical resection of stomach, duodenum or pancreas; or (UGI) bypass.&#xD;
&#xD;
          -  Patients with other important disease, which may interfere with the study (especially&#xD;
             diabetes and renal impairment). Alcoholism, drug abuse or any other circumstances,&#xD;
             which may compromise the patient's ability to comply with the study requirements.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients experiencing diarrhoea within one month since enrolment date&#xD;
&#xD;
          -  Use of glucagon-like peptide 2 (GLP2), growth hormone (GH) or glutamine or&#xD;
             triglycerides&#xD;
&#xD;
          -  Coeliac Disease, Crohn's disease or infectious intestinal disease&#xD;
&#xD;
          -  Patients on steroids or FANS&#xD;
&#xD;
          -  Oral feeding&gt;1.0-fold the estimated basal metabolic rate as assessed using Harris and&#xD;
             Benedict equation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cinzia Papadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Parma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alastair Forbes, BSc MD FRCP ILTM</last_name>
    <role>Study Chair</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Di Sabatino, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, University of Zambia School of Medicine, University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <state>Lusaka province</state>
        <zip>P/B RW1X</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 2, 2009</study_first_submitted>
  <study_first_submitted_qc>January 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2009</study_first_posted>
  <last_update_submitted>January 2, 2009</last_update_submitted>
  <last_update_submitted_qc>January 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Cinzia Papadia</name_title>
    <organization>Azienda Ospedaliera Universitaria di Parma</organization>
  </responsible_party>
  <keyword>citrulline</keyword>
  <keyword>malabsorption</keyword>
  <keyword>Villous atrophy</keyword>
  <keyword>enteropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Enteropathy</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Sprue, Tropical</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Ileal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

